honokiol liposome lyophilized powder for injection (JRF101) / Jinrui Foundation - LARVOL DELTA

Orphan Designation: treatment of malignant glioma (FDA) - Date Designated: 11/18/2024

Orphan drug • Glioma

Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization. (PubMed, Phytomedicine) - "This study validated the anti-tumor efficacy of Lipo-HNK against NSCLC. Lipo-HNK reduced the infiltration of MDSCs and M2 macrophages by inhibiting the PI3K/Akt pathway and enhanced the therapeutic effects of ICIs. These findings provide evidence and new insights into Lipo-HNK as a promising anti-cancer drug for NSCLC treatment, highlighting its potential to overcome resistance to current ICI therapies."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • IL10 • IL4 • MRC1 • TGFB1